G2X TAKE: Looking to leverage Jeff Turner’s experience managing a portfolio of 10+ contracts with revenues in excess of $100 million a year, A Square Group, a woman-owned small business provider of Healthcare, technology, and management consulting services, adds a new VP of Health (CMS Programs).
Jeff brings responsibility for delivery oversight of major enterprise application development projects such as Fraud Prevention System (FPS2), Medicare Beneficiary Database Suite of Systems (MBDSS), Business Operations Support Contract (BOSC) and Physician Value among others.
Prior roles include:
Director, CMS Programs – Northrop Grumman
Program Manager – Northrop Grumman
Project Manager - CGI
In 2019 A Square Group (ASG) recruited experienced Federal Health growth leader Russ Sanford, as they looked to leverage his years of proven performance in Healthcare IT business development, capture management, operations and service delivery management. The company also recently added Vivek Pillai, an experienced corporate executive, program manager and solutions architect with over 20 years of leadership experience.
A Square Group’s recent past performance with CMS includes a $25M HIE and Financial Management Operational Analytics contract and a recent $14.3M CMS CCIIO Federally-Facilitated Marketplaces Agent Brokers Program Support award.
A Square Group, a small business Prime on both the $25B SPARC IDIQ and the CMS Measure and Instrument Development & Support (MIDS) IDIQ, was named last summer to the list of Small Business awardees for $20B CIO-SP3 SB On-Ramp.
This interview with Sara Singh, Founder and President of A Square Group (ASG), and its COO, Mandeep Singh, discusses the company’s recent awards and efforts with the National Institutes of Health, National Institute for Mental Health (NIMH) around mobile application, Data Collection and Analytics platforms. The interview included the opportunity to dig into the clinical side with Melissa A. Brotman, Ph.D. Assistant Clinical Investigator and Director of NIH’s Neuroscience and Novel Therapeutics Unit (NNT). Read the interview here.
Reply to this post...